ClinicalTrials.gg
Sign In
RecruitingNCT07894666SAHOT-FRUpdated Oct 26, 2026

French Validation of the SAHOT Outcome Scale After Subarachnoid Haemorrhage

An observational study in Subarachnoid Hemorrhage, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 26, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Study summary

Survivors of subarachnoid haemorrhage (SAH) frequently experience cognitive, psychological, physical and social sequelae, but no French-language instrument covers all these dimensions. The SAHOT (Subarachnoid Haemorrhage Outcome Tool), developed and validated in English, is a SAH-specific patient-reported outcome measure. This prospective single-centre cohort study aims to validate the French translation of the SAHOT in adult patients seen at a follow-up consultation within 12 months after a SAH of any aetiology. The primary objective is to assess the internal consistency of the French SAHOT. Seventy patients will be included; accompanying relatives may also be included to complete a proxy version of the questionnaire.

02

Conditions studied

  • Subarachnoid Hemorrhage
03

In context

Subarachnoid Hemorrhage

510 studies on the registry are indexed under Subarachnoid Hemorrhage; 128 are open to participants now.

This study's planned enrollment of 70 is below the median of 120 across 226 observational studies indexed under Subarachnoid Hemorrhage.

Browse Subarachnoid Hemorrhage studies →

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.

Browse Fondation Ophtalmologique Adolphe de Rothschild studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with a subarachnoid haemorrhage of any aetiology within the previous 12 months, seen at a follow-up consultation in the interventional neuroradiology department of the Hôpital Fondation Adolphe de Rothschild (Paris, France), and, when applicable, their accompanying relatives.

Eligibility criteria

Inclusion Criteria (patients):

  • Age over 18 years
  • Subarachnoid haemorrhage of any aetiology
  • Onset less than 12 months before inclusion
  • Seen in consultation at the Hôpital Fondation Adolphe de Rothschild
  • Judged able to complete a self-administered questionnaire by the evaluating clinician
  • Informed and not opposed to participation (or relative's non-opposition if the patient is under guardianship and/or unable to consent)

Inclusion Criteria (relatives):

  • Age over 18 years
  • Relative / caregiver of a patient with subarachnoid haemorrhage within the previous 12 months
  • Attending the follow-up consultation of an included patient
  • Informed and not opposed to participation

Exclusion Criteria (patients and relatives):

  • Non-French-speaking
  • Psychiatric disorder judged incompatible with completion of the questionnaires by the investigator
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Internal consistency of the French version of the SAHOT

    Time frame: At inclusion (follow-up consultation within 12 months after subarachnoid haemorrhage)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.

Of 116 non-industry observational studies under Subarachnoid Hemorrhage, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 127. This study's planned 24 months is below that.

Counting every sponsor, half of 119 studies reached it within 40 months; a quarter within 19 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Oct 26, 2026
StartActual
Sep 28, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07894666
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Sep 28, 2026
Primary completion
Oct 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Emma Gentric
Contact
egentric@for.paris
+33 1 48 03 65 00 ext. 7260

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Subarachnoid Hemorrhage →

Other studies from this sponsor

Fondation Ophtalmologique Adolphe de Rothschild →

Start the discussion